The conversation the industry
needs to be having — out loud
FC Lim speaks on pharmaceutical and biotechnology digital investment strategy: what determines level before the first system is selected, and why most digital investments land where they do.
ISPE Singapore Conference & Exhibition 2026
FC Lim is participating in the ISPE Singapore Annual Conference in a personal capacity, bringing the cross-case perspective developed over two decades of pharmaceutical and biotechnology manufacturing IT engagements across Asia, Europe, and Australia.
The conference brings together pharmaceutical and biotechnology professionals across manufacturing, engineering, quality, regulatory, and digital functions. It is the primary industry gathering in the region for the exchange of practical knowledge.
Participating in personal capacity. Before the Next Digital Investment is available now as a free eBook — delegates at the conference will be pointed to the download.
eBook available to delegates. Before the Next Digital Investment — seven case studies from pharmaceutical and biotechnology digital investment, organised by the FC Model™ — is free to download, with the link shared at the conference.
Topics drawn from practice, not theory
Every speaking engagement draws on real cases — anonymised, cross-industry, and structured through the FC Model™ diagnostic framework. The questions are practical. The patterns are recurring. The conclusions are uncomfortable in the best way.
Why pharmaceutical digital investment gets stuck at Level 1
The structural reasons most digital investments in pharmaceutical manufacturing deliver compliance without capability — and what it takes to move beyond them. Based on pattern analysis across seven cross-company cases.
The decision that was not made at the beginning
The data standards choices, integration architecture decisions, and governance structures that are either made before the RFP or paid for — expensively and reactively — for years afterward. A diagnostic framework for site heads, VPs, and CFOs.
The FC Model: from compliant to competitive
A 3×3 maturity diagnostic for pharmaceutical manufacturing digital investment. Three levels — Compliant, Capable, Competitive — across three value dimensions: Customer Value, Product Value, and Operational Value.
The greenfield trap: when a new site is not a fresh start
Greenfield sites have structural advantages — no legacy system debt, no inherited architecture — but most fail to convert the advantage. A case study in how digital investment ambition is set (or not set) before the first contractor arrives.
When the operator is not human: EU GMP Annex 22 and autonomous manufacturing
The regulatory and digital readiness implications of autonomous operations in pharmaceutical manufacturing. Drawing on direct experience from cleanroom robotics R&D under Singapore's BioPIPS framework.
The CFO who changed everything: building the financial case for Level 2
How financial leadership can unlock digital investment ambition — and why the most effective sponsor of Level 2 transformation is often the CFO, not the CIO or site head. A case study of the Asia-Pacific rollout — four countries — inside one global manufacturer's wider transformation.
"The level your digital investment reaches is determined before the first system is selected — not after the last one goes live."— FC Lim, Before the Next Digital Investment (2026)
Conference, workshop, and private session
Speaking engagements are calibrated to the audience — from plenary conference sessions to working sessions for leadership teams navigating a specific investment decision.
Conference keynote or panel
Industry conference presentations and panel participation. Cross-case patterns from pharmaceutical and biotechnology manufacturing digital investment, presented at the level of strategic insight rather than technical prescription.
Workshop facilitation
Structured working sessions with site leadership teams. FC Model diagnostic applied to a specific investment decision or digital programme. Designed to surface the structural questions before the RFP is written.
Private executive session
Confidential briefings for boards, executive leadership, or investor groups. Industry pattern analysis applied to a specific organisation's situation. Useful at the point of a major investment decision or strategic review.
Invite FC Lim to speak at your event or session
Speaking invitations are considered on a selective basis. Priority is given to engagements where the audience is actively engaged in pharmaceutical or biotechnology manufacturing investment decisions — site heads, VPs of Operations, CFOs, quality and regulatory leaders, and digital programme sponsors.
For conference organisers, committee chairs, and executive hosts, a brief description of the event, audience, and proposed theme is the best starting point.
What to include in a speaking enquiry
- Event name, format, and date range
- Expected audience — role, seniority, and industry context
- Proposed theme or session title, if you have one in mind
- Whether the session is public conference, private workshop, or executive briefing
- Any constraints on content — duration, format, or topic focus
- Whether sharing the eBook download link with delegates would be appropriate